HOLOGIC, INC. (NASDAQ:HOLX) Files An 8-K Financial Statements and Exhibits
Item9.01.
| Financial Statements and Exhibits. |
| (a) | Financial Statements of Business Acquired |
The audited consolidated financial statements of Cynosure as of
and for the year ended December31, 2016, the accompanying notes
thereto, and the related Report of Independent Registered Public
Accounting Firm, are filed as Exhibit 99.1 and incorporated
herein by reference to the audited consolidated financial
statements of Cynosure as of December31, 2016 and 2015 and for
each of the years ended December31, 2016, 2015 and 2014 that are
contained in Cynosures Annual Report on Form 10-K for the fiscal
year ended December31, 2016, as filed with the SEC on February28,
2017.
| (b) | Pro Forma Financial Information |
The following unaudited pro forma condensed combined financial
information giving effect to the Merger is being furnished under
this Item9.01(b) as Exhibit 99.2 attached hereto, and shall not
be deemed to be filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall such
information be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange
Act, except as set forth by specific reference in such filing:
|
Unaudited pro forma condensed combined statement of income for the year ended September24, 2016; |
|
Unaudited pro forma condensed combined statement of income for the six months ended April1, 2017; and |
|
Notes to unaudited pro forma condensed combined financial information. |
| (d) | Exhibits |
|
Exhibit Number |
Description |
|
|
23.1 |
Consent of Ernst Young LLP | |
|
99.1 |
Audited consolidated financial statements of Cynosure as of and for the year ended December 31, 2016 (incorporated by reference to the Form 10-K filed by Cynosure with the SEC on February 28, 2017). |
|
|
99.2 |
Unaudited pro forma condensed combined financial information of Hologic. |
About HOLOGIC, INC. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.